Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

HR+ Early Breast Cancer

HR+ early stage Node negative TAILORx Surgery Premenopausal RS 1–15 Endocrine therapy RS 16–25 Some benefit from chemo → ET RS 26+ Chemotherapy (TC) → ET Postmenopausal RS 1–25 Endocrine therapy RS 26+ Chemotherapy (TC) → ET 1–3 positive nodes RxPONDER Surgery Premenopausal RS 1–25 Chemo vs OFS + AI → ET RS 26+ Chemotherapy (TC, ddAC-T) → ET Postmenopausal RS 1–25 Endocrine therapy RS 26+ Chemotherapy → ET 4+ positive nodes Surgery Chemotherapy (ddAC-T) → ET Adjuvant escalation (selected high-risk) Abemaciclib × 2 yr monarchE (N+ high risk) ↗ Ribociclib × 3 yr NATALEE (stage II–III) ↗ Olaparib × 1 yr OlympiA (gBRCA, high risk) ↗